ZA921430B - Process for an industrial-scale preparation of a standardized human von willebrand factor concentrate of very high purity and suitable for therapeutic use - Google Patents

Process for an industrial-scale preparation of a standardized human von willebrand factor concentrate of very high purity and suitable for therapeutic use

Info

Publication number
ZA921430B
ZA921430B ZA921430A ZA921430A ZA921430B ZA 921430 B ZA921430 B ZA 921430B ZA 921430 A ZA921430 A ZA 921430A ZA 921430 A ZA921430 A ZA 921430A ZA 921430 B ZA921430 B ZA 921430B
Authority
ZA
South Africa
Prior art keywords
industrial
high purity
therapeutic use
von willebrand
willebrand factor
Prior art date
Application number
ZA921430A
Other languages
English (en)
Inventor
Miryana Burnouf-Radosevich
Burnouf-Radosevich Miryana
Thierry Burnouf
Burnouf Thierry
Original Assignee
Centre Regional De Transfusion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Regional De Transfusion filed Critical Centre Regional De Transfusion
Publication of ZA921430B publication Critical patent/ZA921430B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA921430A 1991-03-08 1992-02-26 Process for an industrial-scale preparation of a standardized human von willebrand factor concentrate of very high purity and suitable for therapeutic use ZA921430B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9102804A FR2673632A1 (fr) 1991-03-08 1991-03-08 Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.

Publications (1)

Publication Number Publication Date
ZA921430B true ZA921430B (en) 1992-11-25

Family

ID=9410505

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA921430A ZA921430B (en) 1991-03-08 1992-02-26 Process for an industrial-scale preparation of a standardized human von willebrand factor concentrate of very high purity and suitable for therapeutic use

Country Status (29)

Country Link
US (1) US5408039A (de)
EP (1) EP0503991B1 (de)
JP (1) JP3435668B2 (de)
AT (1) AT407115B (de)
AU (1) AU645172B2 (de)
BE (1) BE1004178A3 (de)
BR (1) BR9200770A (de)
CA (1) CA2062340C (de)
CZ (1) CZ283633B6 (de)
DE (2) DE122009000034I2 (de)
DK (1) DK0503991T3 (de)
EE (1) EE03057B1 (de)
EG (1) EG20300A (de)
ES (1) ES2121830T3 (de)
FI (1) FI106721B (de)
FR (1) FR2673632A1 (de)
HU (1) HU215098B (de)
IL (1) IL101043A (de)
IT (1) IT1256692B (de)
LT (1) LT3175B (de)
NL (1) NL300394I1 (de)
NO (1) NO301278B1 (de)
NZ (1) NZ241701A (de)
PL (1) PL168353B1 (de)
RU (1) RU2088590C1 (de)
SA (1) SA92120446B1 (de)
SK (1) SK279533B6 (de)
UA (1) UA27732C2 (de)
ZA (1) ZA921430B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
DE19616540A1 (de) * 1995-11-10 1997-05-15 Immuno Ag Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404358B (de) * 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
DK2130554T3 (da) 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
EP1593388A1 (de) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutische Plasmaproteinkonzentrate mit von-Willebrand-Faktor als Multimere mit hohem Molekulargewicht
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044419B4 (de) 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
DE102004044429B4 (de) * 2004-09-14 2009-04-30 Biotest Ag Verfahren zur Herstellung einer Zusammensetzung enthaltend von Willebrand Faktor
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
JP2010529155A (ja) 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
EP2073015A1 (de) 2007-12-21 2009-06-24 CSL Behring GmbH Diagnostisches In-vitro-Verfahren zur Beurteilung der Von-Willebrand-Krankheit und mit der Von-Willebrand-Krankheit assoziierte Blutungsgefahr und erworbene oder angeborene Plättchenstörungen
US20100273206A1 (en) * 2007-12-21 2010-10-28 Manfred Rauh Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function
CA2728012C (en) 2008-06-24 2017-10-31 Csl Behring Gmbh Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
AU2009313325B2 (en) * 2008-11-07 2014-05-01 Takeda Pharmaceutical Company Limited Factor VIII formulations
IT1396528B1 (it) 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
AU2010284977A1 (en) 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
JP6029674B2 (ja) 2011-10-18 2016-11-24 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
ES2693380T3 (es) 2013-11-08 2018-12-11 Csl Limited Nuevo método para concentrar el factor de von Willebrand o complejos de este
US10253088B2 (en) 2014-07-02 2019-04-09 CSL Behring Lengnau AG Modified von Willebrand Factor
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
EP3362464B1 (de) * 2015-10-15 2021-04-28 Plasma Technologies LLC Verfahren zur extraktion von proteinen aus blutplasma
BR112018013822A2 (pt) 2016-01-07 2018-12-11 Csl Behring Recombinant Facility Ag ?polipeptídeo modificado, complexo, composição farmacêutica, métodos para tratamento de um distúrbio hemorrágico, para produção de um polipeptídeo e para aumento da meia-vida do fator viii, uso de um polipeptídeo modificado, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira?
EP3400002B1 (de) 2016-01-07 2022-02-02 CSL Behring Lengnau AG Trunkierter mutierter von-willebrand-faktor
CN105622747A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种vWF活性保护液
CN105622746A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种从冷沉淀提取凝血因子ⅷ的废料中提取人血管性血友病因子的制备工艺
CN105541997A (zh) * 2016-02-04 2016-05-04 江西博雅生物制药股份有限公司 一种高纯度和高活性血管性血友病因子的制备工艺
EP3488858A1 (de) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies Eine von-willebrand-faktor-zusammensetzung und deren verwendung zur behandlung einer durch angiogenese verursachte krankheit
CN114249812B (zh) * 2020-09-22 2023-09-15 四川远大蜀阳药业有限责任公司 一种降低vWF制品中IgM含量的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61166542A (ja) * 1985-01-18 1986-07-28 Hitachi Chem Co Ltd 感光性組成物
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5006642A (en) * 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus

Also Published As

Publication number Publication date
ES2121830T3 (es) 1998-12-16
SK279533B6 (sk) 1998-12-02
ATA43692A (de) 2000-05-15
UA27732C2 (uk) 2000-10-16
CZ283633B6 (cs) 1998-05-13
DE69227055T2 (de) 1999-04-22
DE122009000034I2 (de) 2011-06-16
CA2062340C (fr) 2000-05-09
US5408039A (en) 1995-04-18
LT3175B (en) 1995-02-27
ITTO920189A1 (it) 1993-09-06
DE122009000034I1 (de) 2010-04-08
JP3435668B2 (ja) 2003-08-11
IT1256692B (it) 1995-12-12
AT407115B (de) 2000-12-27
EP0503991B1 (de) 1998-09-23
BR9200770A (pt) 1992-11-17
PL293738A1 (en) 1992-09-21
AU645172B2 (en) 1994-01-06
HU9200767D0 (en) 1992-05-28
PL168353B1 (pl) 1996-02-29
FR2673632A1 (fr) 1992-09-11
RU2088590C1 (ru) 1997-08-27
CA2062340A1 (fr) 1992-09-09
EP0503991A1 (de) 1992-09-16
NO920867L (no) 1992-09-09
CS56892A3 (en) 1992-09-16
FI106721B (fi) 2001-03-30
EG20300A (fr) 1998-10-31
JPH0597696A (ja) 1993-04-20
BE1004178A3 (fr) 1992-10-06
ITTO920189A0 (it) 1992-03-06
AU1113192A (en) 1992-09-10
NZ241701A (en) 1994-10-26
IL101043A (en) 1997-02-18
DE69227055D1 (de) 1998-10-29
HU215098B (hu) 1998-09-28
EE03057B1 (et) 1997-12-15
DK0503991T3 (da) 1999-06-14
NO301278B1 (no) 1997-10-06
NL300394I1 (nl) 2009-09-01
HUT63176A (en) 1993-07-28
NO920867D0 (no) 1992-03-05
SA92120446B1 (ar) 2004-05-04
FI920992A (fi) 1992-09-09
IL101043A0 (en) 1992-11-15
LTIP266A (en) 1994-07-15
FI920992A0 (fi) 1992-03-06
FR2673632B1 (de) 1995-05-05

Similar Documents

Publication Publication Date Title
ZA921430B (en) Process for an industrial-scale preparation of a standardized human von willebrand factor concentrate of very high purity and suitable for therapeutic use
GR3006910T3 (en) Preparation of a concentrate of high-purity human factor IX and of other plasma proteins
EP0532466A3 (en) Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
HU893408D0 (en) Process for the production of glycosamino-glucane salts and medical preparations containing them
HU894124D0 (en) Process for producing peptides and pharmaceutical preparatives containing these peptides
HUT65736A (en) Process for producing 2-saccharinylmethyl-aryl and aryloxy acetates and pharmaceutical preparations containing them
CS202292A3 (en) Novel pyrrolopyrazines, process of their preparation and medicaments based thereon
IL77534A (en) Growth hormone-releasing peptides and process for their preparation
HUT44483A (en) Process for production of derivatives of 2n (benzolsulphonil)-antranil-acid-amid and medical preparatives containing them
GB2216420B (en) Treatment of establised osteoroposis using progestins
ZM10686A1 (en) New orth-anisamides process for their preparation and their therapeutic application
AU1757592A (en) Therapeutic fragments of von willebrand factor
EP0520419A3 (en) Production of unsaturated cycloaliphatic esters and derivatives thereof
GR862287B (en) Novel n-alkylated tripeptides process for their preparation medicaments containing them and their use
HU9200230D0 (en) Process for the production of 3-amino-sidnonimine derivatives and medical preparations containing them
HU896683D0 (en) Process for the preparation of new therapeutical preparations
HUT48276A (en) Process for production of rhenin-hindering peptides and medical preparatives containing them
GB2171700B (en) Unsaturated cycloaliphatic derivatives
PT84353A (en) Purified human angiogenic factor method for its preparation andpharmaceutical preparations
CS432988A1 (en) Method of diethylenetriaminopentaacetic acid's and ethylenediaminotetraacetic acid's bicyclic anhydrides preparation
GB2223492B (en) Preparation of carboxylic acid amides
HU893527D0 (en) Process for the production of proburzine and pharmaceutical preparations containing thereof
PT81505A (en) Process of preparation of esters of diethyleneglycol
BG44477A1 (en) Method and device for manufacture of combined fancy threads
HU9200116D0 (en) Process for the production of novel kinoline-8-carbonic acid derivatives and medical preparations containing them